<SEC-DOCUMENT>0001193125-18-268254.txt : 20180906
<SEC-HEADER>0001193125-18-268254.hdr.sgml : 20180906
<ACCEPTANCE-DATETIME>20180906162058
ACCESSION NUMBER:		0001193125-18-268254
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180905
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180906
DATE AS OF CHANGE:		20180906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		181057761

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d616647d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): September&nbsp;5, 2018</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CERUS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-21937</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">68-0262011</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2550 Stanwell Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Concord, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94520</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code (925)
<FONT STYLE="white-space:nowrap">288-6000</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name
or Former Address, if Changed Since Last Report)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(17&nbsp;CFR&nbsp;&#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On September&nbsp;5, 2018, the Board of Directors (the
&#147;Board&#148;) of Cerus Corporation (the &#147;Company&#148;), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Timothy L. Moore to the Board, effective immediately. Mr.&nbsp;Moore will serve in
the class of directors whose term of office expires at the Company&#146;s 2020 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr.&nbsp;Moore currently serves
as executive vice president, technical operations for Kite, a Gilead Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s Amended and Restated <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, adopted by the Board on March&nbsp;2, 2018 (the &#147;Director Policy&#148;), as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of the Board, Mr.&nbsp;Moore
is entitled to receive an annual cash retainer in the amount of $40,000 for his service as a Board member, paid in quarterly installments and <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of days Mr.&nbsp;Moore will serve on
the Board. In addition to the cash retainer, Mr.&nbsp;Moore will be reimbursed for reasonable expenses incurred in attending meetings of the Board. As a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, Mr.&nbsp;Moore is not entitled to
perquisites or retirement benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his election, Mr.&nbsp;Moore received an initial stock option grant under the
Company&#146;s Amended and Restated 2008 Equity Incentive Plan (the &#147;2008 Plan&#148;) and pursuant to the Director Policy for the number of shares of the Company&#146;s common stock equal to (i) $93,750, divided by (ii)&nbsp;the Black-Scholes
value of a stock option share, determined using the average daily closing sales price per share of the Company&#146;s common stock for the thirty (30)&nbsp;market trading days immediately prior to the grant date (the &#147;Average <FONT
STYLE="white-space:nowrap">30-Day</FONT> Price&#148;), with the resulting number rounded down to the nearest whole share, with such stock option vesting in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;equal monthly installments
following the date of grant, subject to Mr.&nbsp;Moore&#146;s continued service on the Board. Mr.&nbsp;Moore also received a restricted stock unit award (&#147;RSU&#148;) for the number of shares of the Company&#146;s common stock equal to (i)
$93,750, divided by (ii)&nbsp;the Average <FONT STYLE="white-space:nowrap">30-Day</FONT> Price, with the resulting number rounded down to the nearest whole share, with such RSU vesting in three (3)&nbsp;annual installments following the date of
grant, also subject to Mr.&nbsp;Moore&#146;s continued service on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Moore will automatically receive pursuant to the
Director Policy an option to purchase the number of shares of the Company&#146;s common stock equal to (i) $62,500, divided by (ii)&nbsp;the Black-Scholes value of a stock option share, determined using the Average
<FONT STYLE="white-space:nowrap">30-Day</FONT> Price, with the resulting number rounded down to the nearest whole share (the &#147;Annual Option&#148;), and an RSU for the number of shares of the Company&#146;s common stock equal to (x) $62,500,
divided by (y)&nbsp;the Average <FONT STYLE="white-space:nowrap">30-Day</FONT> Price, with the resulting number rounded down to the nearest whole share (the &#147;Annual RSU&#148;), on the date of each annual meeting of the stockholders of the
Company if he has been a member of the Board for at least twelve (12)&nbsp;months prior to the date of the applicable annual meeting and is serving as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director as of such date. The Annual Option
will vest in twelve equal monthly installments beginning one month from the date of grant, with full vesting to occur on the earlier of one year from the grant date, or the trading day immediately prior to date of the next annual meeting. The Annual
RSU will vest 100% upon the earlier of one year from the grant date, or the trading day immediately prior to date of the next annual meeting. Annual equity grants under the Director Policy are
<FONT STYLE="white-space:nowrap">non-discretionary.</FONT> All options granted pursuant to the Director Policy have a term of ten years, have an exercise price equal to 100% of the fair market value of the Company&#146;s common stock on the date of
grant and are subject to the terms of the 2008 Plan. In the event&nbsp;of a &#147;change in control&#148; of the Company, as defined by the 2008 Plan, all outstanding equity held by Mr.&nbsp;Moore will become fully vested immediately prior to such
change in control event, subject to Mr.&nbsp;Moore&#146;s &#147;continuous service,&#148; as defined by the 2008 Plan, to the Company at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Mr.&nbsp;Moore&#146;s election to the Board, he and the Company will enter into the Company&#146;s standard indemnity
agreement for the Company&#146;s directors and officers, which requires the Company to indemnify Mr.&nbsp;Moore, under the circumstances and to the extent provided for therein, against certain expenses and other amounts incurred by Mr.&nbsp;Moore as
a result of being made a party to certain actions, suits, proceedings and the like by reason of his position as a director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing the appointment of Mr.&nbsp;Moore to the Board is attached as Exhibit 99.1 to this current report and
is incorporated herein by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following exhibit is furnished with this report: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d616647dex991.htm">Press release, dated September&nbsp;6, 2018, entitled &#147;Cerus Appoints Timothy L. Moore to Board of Directors.&#148; </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CERUS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: September&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chrystal Menard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chrystal Menard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer and General Counsel</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d616647dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g616647cerus.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cerus Appoints Timothy L. Moore to Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONCORD, CA, September&nbsp;6, 2018 - Cerus Corporation (Nasdaq: CERS) today announced the appointment of Timothy L. Moore to its Board of Directors.
Mr.&nbsp;Moore, who currently serves as executive vice president, technical operations for Kite, a Gilead Company, brings over three decades of experience in engineering, manufacturing, and technical operations in the biopharmaceutical industry.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Following an extensive search, we are delighted to welcome Tim to Cerus&#146; Board of Directors,&#148; said Daniel Swisher, Chair of the Board.
&#147;Tim brings a wealth of manufacturing operations experience and an impressive track record of success in helping companies in the life sciences industry scale their global manufacturing and supply chain operations. Tim&#146;s extensive
experience with plasma derivative and cell therapy production lines in multiple geographies will serve Cerus well, as we strive to establish the INTERCEPT blood system as the global standard of care for transfused blood components.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am looking forward to joining the Cerus Board and supporting the Company&#146;s strategic plan, including scaling the operational infrastructure for
INTERCEPT and launching their red cell product,&#148; commented Timothy L. Moore. &#147;Cerus&#146; INTERCEPT product portfolio is set to transform blood safety and availability across the globe, and I am excited to work with the company to achieve
its next stage of growth.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to his current position at Kite where he has led the global manufacturing effort for the launch of Kite&#146;s
revolutionary Yescarta product, Mr.&nbsp;Moore served 12 years in various engineering, supply chain and manufacturing leadership roles at Genentech, most recently as senior vice president and head of global technical operations, biologics unit.
Previously in his career, Mr.&nbsp;Moore held senior manufacturing, operations, and engineering positions at CSL Ltd, Armour Pharmaceuticals, and Merck. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT CERUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk
of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to
inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See
http://www.cerus.com for information about Cerus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Lee &#150; Investor Relations Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">925-288-6137</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g616647cerus.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g616647cerus.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?\_R_P#?O_Z]<G]BR_G_  _X)T_VM'^3\0_X0>3_ )_E_P"_?_UZ/[%E_/\
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%@T ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
